Imago BioSciences, Inc. Research and Development Expense
Imago BioSciences, Inc. reported Research and Development Expense of $13.45 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-09
- Imago BioSciences, Inc. research and development expense for the quarter ending 2022-09-30 was $13.45M, a 54.99% increase year-over-year.
- Imago BioSciences, Inc. research and development expense for the quarter ending 2022-06-30 was $9.68M, a 36.31% increase year-over-year.
- Imago BioSciences, Inc. research and development expense for the quarter ending 2022-03-31 was $12.50M, a 161.99% increase year-over-year.
- Imago BioSciences, Inc. research and development expense for the quarter ending 2021-12-31 was $11.71M, a 173.98% increase year-over-year.
- Imago BioSciences, Inc. research and development expense for fiscal 2021 was $32.26M, a 116.57% increase from fiscal 2020.
- Imago BioSciences, Inc. research and development expense for fiscal 2020 was $14.90M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $13.45M 10-Q · filed 2022-11-09 | $23.13M derived: sum of 2 quarters · filed 2022-11-09 | $35.63M 10-Q · filed 2022-11-09 | $47.34M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $9.68M 10-Q · filed 2022-08-12 | $22.18M 10-Q · filed 2022-08-12 | $33.89M derived: sum of 3 quarters · filed 2022-08-12 | $42.57M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $12.50M 10-Q · filed 2022-05-12 | $24.21M derived: sum of 2 quarters · filed 2022-05-12 | $32.89M derived: sum of 3 quarters · filed 2022-11-09 | $39.99M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | $11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $20.39M derived: sum of 2 quarters · filed 2022-11-09 | $27.49M derived: sum of 3 quarters · filed 2022-11-09 | $32.26M 10-K · filed 2022-03-24 |
| 2021-09-30 | $8.68M 10-Q · filed 2022-11-09 | $15.78M derived: sum of 2 quarters · filed 2022-11-09 | $20.55M 10-Q · filed 2022-11-09 | $24.82M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $7.10M 10-Q · filed 2022-08-12 | $11.87M 10-Q · filed 2022-08-12 | $16.14M derived: sum of 3 quarters · filed 2022-08-12 | $19.72M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $4.77M 10-Q · filed 2022-05-12 | $9.05M derived: sum of 2 quarters · filed 2022-05-12 | $12.62M derived: sum of 3 quarters · filed 2022-05-12 | $15.98M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $7.85M derived: sum of 2 quarters · filed 2022-03-24 | $11.20M derived: sum of 3 quarters · filed 2022-03-24 | $14.90M 10-K · filed 2022-03-24 |
| 2020-09-30 | $3.58M 10-Q · filed 2021-11-10 | $6.93M derived: sum of 2 quarters · filed 2021-11-10 | $10.62M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.35M 10-Q · filed 2021-08-19 | $7.05M 10-Q · filed 2021-08-19 |